These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides. Berman CL; Antonsson M; Batkai S; Bosgra S; Chopda GR; Driessen W; Foy J; Hassan C; Hu XS; Jang HG; Meena ; Sanseverino M; Thum T; Wang Y; Wild M; Wu JT Nucleic Acid Ther; 2023 Oct; 33(5):287-305. PubMed ID: 37590469 [TBL] [Abstract][Full Text] [Related]
4. Meeting report: 1st workshop of the peptide ADME discussion group. Sonesson A; Brady K; Bjørnsdottir I; Christensen JK Xenobiotica; 2021 Jan; 51(1):122-125. PubMed ID: 32048540 [TBL] [Abstract][Full Text] [Related]
5. Meeting report: 2nd workshop of the peptide ADME discussion group. Sonesson A; Bjørnsdottir I; Christensen JK Xenobiotica; 2021 Jan; 51(1):1-4. PubMed ID: 32571130 [TBL] [Abstract][Full Text] [Related]
6. Meeting report: 3rd workshop of the peptide ADME discussion group. Sonesson A; Bjørnsdottir I; Christensen JK Xenobiotica; 2021 Dec; 51(12):1470-1474. PubMed ID: 34919491 [TBL] [Abstract][Full Text] [Related]
7. Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives. Bolleddula J; Brady K; Bruin G; Lee A; Martin JA; Walles M; Xu K; Yang TY; Zhu X; Yu H Drug Metab Dispos; 2022 Jun; 50(6):837-845. PubMed ID: 35149541 [TBL] [Abstract][Full Text] [Related]
8. Meeting report of the second European biotransformation workshop. Walles M; Pähler A; Isin EM; Weidolf L Xenobiotica; 2022 Apr; 52(4):426-431. PubMed ID: 35410573 [TBL] [Abstract][Full Text] [Related]
9. Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. Migliorati JM; Liu S; Liu A; Gogate A; Nair S; Bahal R; Rasmussen TP; Manautou JE; Zhong XB Drug Metab Dispos; 2022 Jun; 50(6):888-897. PubMed ID: 35221287 [TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Shadid M; Badawi M; Abulrob A Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1281-1292. PubMed ID: 34643122 [TBL] [Abstract][Full Text] [Related]
11. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs. Takakusa H; Iwazaki N; Nishikawa M; Yoshida T; Obika S; Inoue T Nucleic Acid Ther; 2023 Apr; 33(2):83-94. PubMed ID: 36735616 [TBL] [Abstract][Full Text] [Related]
12. Factors Influencing ADME Properties of Therapeutic Antisense Oligonucleotides: Physicochemical Characteristics and Beyond. Jiang R; Hooshfar S; Rebecca Eno M; Yun C; Sonego Zimmermann E; Shinkyo R Curr Drug Metab; 2023; 24(7):536-552. PubMed ID: 37076460 [TBL] [Abstract][Full Text] [Related]
13. Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics. Marlowe JL; Akopian V; Karmali P; Kornbrust D; Lockridge J; Semple S Nucleic Acid Ther; 2017 Aug; 27(4):183-196. PubMed ID: 28609186 [TBL] [Abstract][Full Text] [Related]
14. Use of radioactive compounds and autoradiography to determine drug tissue distribution. Solon EG Chem Res Toxicol; 2012 Mar; 25(3):543-55. PubMed ID: 22280496 [TBL] [Abstract][Full Text] [Related]
15. Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the Fowler S; Brink A; Cleary Y; Günther A; Heinig K; Husser C; Kletzl H; Kratochwil N; Mueller L; Savage M; Stillhart C; Tuerck D; Ullah M; Umehara K; Poirier A Drug Metab Dispos; 2022 Jan; 50(1):65-75. PubMed ID: 34620695 [TBL] [Abstract][Full Text] [Related]
16. Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development. Andersson S; Antonsson M; Elebring M; Jansson-Löfmark R; Weidolf L Drug Discov Today; 2018 Oct; 23(10):1733-1745. PubMed ID: 29852223 [TBL] [Abstract][Full Text] [Related]
17. Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods. Tsaioun K; Blaauboer BJ; Hartung T ALTEX; 2016; 33(4):343-358. PubMed ID: 27806179 [TBL] [Abstract][Full Text] [Related]
18. Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Goyenvalle A; Jimenez-Mallebrera C; van Roon W; Sewing S; Krieg AM; Arechavala-Gomeza V; Andersson P Nucleic Acid Ther; 2023 Jan; 33(1):1-16. PubMed ID: 36579950 [TBL] [Abstract][Full Text] [Related]
19. Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics. Ramsden D; Belair DG; Agarwal S; Andersson P; Humphreys S; Dalmas DA; Stahl SH; Maclauchlin C; Cichocki JA ALTEX; 2022; 39(2):273–296. PubMed ID: 34766620 [TBL] [Abstract][Full Text] [Related]
20. Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment. Tessier Y; Achanzar W; Mihalcik L; Amuzie C; Andersson P; Parry JD; Moggs J; Whiteley LO Nucleic Acid Ther; 2021 Feb; 31(1):7-20. PubMed ID: 33054599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]